论文部分内容阅读
目的探讨米非司酮联合宫瘤消胶囊治疗子宫肌瘤患者的临床疗效、肌瘤体积变化及预后情况。方法选取2015年6月-2016年6月该院诊治的156例子宫肌瘤患者临床资料,分为对照组和观察组,每组各78例。对照组单独使用米非司酮治疗,观察组在对照组基础上联合宫瘤消胶囊治疗,比较两组临床疗效、肌瘤体积变化及预后情况。结果治疗后观察组黄体生成素、血清促卵泡素等激素水平(13.15±1.60)U/L、(13.20±2.40)U/L均优于对照组,两组比较差异均有统计学意义(均P<0.05);两组治疗后肌瘤体积、子宫体积均较治疗前缩小,且观察组缩小幅度更大,差异均有统计学意义(P<0.05);观察组总体健康评分(84.40±15.35)分,优于对照组的(65.35±13.03)分,两组比较差异有统计学意义(P<0.05)。结论米非司酮与宫瘤消胶囊联合使用对子宫肌瘤患者疗效显著,能够优化患者激素水平,缩小肌瘤体积,且提高患者预后生活质量,具有临床推广价值。
Objective To investigate the clinical efficacy of mifepristone combined with Miyaoma capsule in the treatment of uterine fibroids, fibroid volume changes and prognosis. Methods The clinical data of 156 cases of uterine fibroids diagnosed and treated in our hospital from June 2015 to June 2016 were divided into control group and observation group, 78 cases in each group. The control group was treated with mifepristone alone. The observation group was treated with Gongyu Xiaozhu capsule on the basis of the control group. The clinical curative effect, the change of fibroids volume and the prognosis of the two groups were compared. Results After treatment, the levels of luteinizing hormone (LH) and serum FSH (13.15 ± 1.60) U / L and (13.20 ± 2.40) U / L in the observation group were significantly higher than those in the control group, with significant difference between the two groups (P < 0.05). After treatment, the volume of myoma and the volume of uterus in both groups decreased compared with that before treatment, and the difference between the two groups was statistically significant (P <0.05). The overall health score of the observation group was 84.40 ± 15.35 (65.35 ± 13.03) in the control group, the difference between the two groups was statistically significant (P <0.05). Conclusion The combination of mifepristone and Gongyu Xiao Capsule has significant curative effect on patients with uterine fibroids, which can optimize hormone levels, reduce the volume of fibroids, and improve the quality of life of patients with prognosis, and has clinical value of popularization.